



HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250
e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

SAFETY DATA SHEET

Section 1: Identification	
Section 1, Identification	
GHS Product identifier	Drospirenone and Ethinyl Estradiol Tablets USP
Trade Name	3 mg/0.02 mg
Recommended use	Not applicable
Manufacturer	Pharmaceutical product to prevent pregnancy.
Distributor	Cyndeia Camber Consumer care, Inc., Piscatway, NJ 08854
Section 2: Hazard(s) Identification	
Section 2, Hazard(s)identification	
Fire and Explosion	Expected to be non-combustible
Health	<p>Do not prescribe Drospirenone and Ethinyl Estradiol Tablets USP to women who are known to have the following:</p> <ul style="list-style-type: none">• Renal impairment• Adrenal insufficiency• A high risk of arterial or venous thrombotic diseases. <p>Examples include women who are known to:</p> <p>Smoke, if over age 35</p> <p>Have deep vein thrombosis or pulmonary embolism, now or in the past</p> <p>Have cerebrovascular disease</p> <p>Have coronary artery disease</p> <p>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)</p> <p>Have inherited or acquired hypercoagulopathies</p> <p>Have uncontrolled hypertension</p> <p>Have diabetes mellitus with vascular disease</p> <p>Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35</p>



HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250
e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

Environment	<ul style="list-style-type: none">• Undiagnosed abnormal uterine bleeding• Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past• Liver tumors, benign or malignant, or liver disease• Pregnancy, because there is no reason to use COCs during pregnancy <p>No information is available about the potential of this product to produce adverse environmental effects.</p>
--------------------	--

Section 3: Composition/Information on Ingredients

Ingredients	CAS
Drospirenone USP	67392-87-4
Ethinyl Estradiol USP	57-63-6

Section 4: First-Aid Measures

Section 4, First-aid measures	
Inhalation	Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.
Skin Contact	Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.
Eye Contact	Flush eyes with plenty of water. Get medical attention.
Ingestion	If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention
NOTES TO HEALTH PROFESSIONALS	
Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital



HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250
e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

OVERDOSAGE	<p>signs, blood gases, serum electrolytes, etc.</p> <p>There have been no reports of serious ill effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.</p> <p>DRSP is a spironolactone analogue which has anti-mineralocorticoid properties. Serum concentration of potassium and sodium, and evidence of metabolic acidosis, should be monitored in cases of Overdose.</p>
Section 5: Fire-Fighting Measures	
Section 5, Fire-fighting measures	
Fire and Explosion Hazards	Assume that this product is capable of sustaining combustion.
Extinguishing Media	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
Special Firefighting Procedures	<p>For single units (packages): No special requirements needed.</p> <p>For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.</p>
Hazardous Combustion Products	Hazardous combustion or decomposition products are expected when the product is exposed to fire.
Section 6: Accidental Release Measures	
Section 6, Accidental release measures	
Personal precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labeled container for recovery or disposal.



HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250
e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

Section 7: Handling and Storage

Section 7, Handling and storage

Handling	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
Storage	Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature].

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form	How Supplied Drospirenone and ethinyl estradiol tablets USP, 3 mg/0.02 mg is available in 1x28's - carton (NDC 31722-934-31) and 3x 28's – carton (NDC 31722-934-32). Each pack (28 film-coated tablets) contains in the following order: <ul style="list-style-type: none">• 24 active pink, round, biconvex, film-coated tablets, debossed with 20 on one side each containing 3 mg drospirenone and 0.02 mg ethinyl estradiol• 4 inert White, round, biconvex, film-coated White, round, biconvex, film-coated tablet marked with PL on one side
----------------------	---

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility	In a 24 month oral carcinogenicity study in mice dosed with 10 mg/kg/day DRSP alone or 1 + 0.01, 3 + 0.03 and 10 + 0.1 mg/kg/day of DRSP and EE, 0.1 to 2 times the exposure (AUC of DRSP) of women taking a contraceptive dose, there was an increase in carcinomas of the harderian gland in the group that received the high dose of DRSP alone. In a similar study in rats given 10 mg/kg/day DRSP
---	---



HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.
Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250
e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

alone or 0.3 + 0.003, 3 + 0.03 and 10 + 0.1 mg/kg/day DRSP and EE, 0.8 to 10 times the exposure of women taking a contraceptive dose, there was an increased incidence of benign and total (benign and malignant) adrenal gland pheochromocytomas in the group receiving the high dose of DRSP. Mutagenesis studies for DRSP were conducted *in vivo* and *in vitro* and no evidence of mutagenic activity was observed.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name	: N/A
IATA UN/ID No	: N/A
IATA Hazard Class	: N/A
IATA Packaging Group	: N/A
IATA Label	: N/A

IMDG - Not Regulated

IMDG Proper shipping Name	: N/A
IMDG UN/ID No	: N/A
IMDG Hazard Class	: N/A
IMDG Flash Point	: N/A
IMDG Label	: N/A

DOT - Not Regulated

DOT Proper shipping Name	: N/A
DOT UN/ID No	: N/A
DOT Hazard Class	: N/A
DOT Flash Point	: N/A
DOT Packing Group	: N/A
DOT Label	: N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

Issue Date : 05-04-2019

Version : 00

Further information



HETERO LABS LIMITED

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA.

Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250

e-mail : contact@heterodrugs.com URL : <http://www.heterodrugs.com>

Revision note: New issue

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Labs Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Labs Limited reserves the right to revise this SDS.